<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00706667</url>
  </required_header>
  <id_info>
    <org_study_id>StV 07-2008</org_study_id>
    <nct_id>NCT00706667</nct_id>
  </id_info>
  <brief_title>Intravenous Ferric Carboxymaltose (Ferinject®) With or Without Erythropoietin in Patients Undergoing Orthopaedic Surgery</brief_title>
  <official_title>Intravenous Ferric Carboxymaltose (Ferinject®) With or Without Erythropoietin for the Correction of Preoperative Anaemia in Patients Undergoing Orthopaedic Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Vifor Pharma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study Design: Single-centre, block randomised, blinded, controlled, phase IIIb, parallel&#xD;
      group pilot study.&#xD;
&#xD;
      Primary Objective:&#xD;
&#xD;
      • To evaluate the effect of the administration of ferric carboxymaltose (Ferinject®) with or&#xD;
      without erythropoietin vs. no treatment (standard therapy) on the preoperative anaemia status&#xD;
      in patients undergoing orthopaedic surgery&#xD;
&#xD;
      Secondary Objective:&#xD;
&#xD;
        -  To gain informations for the design of a possible follow-up study&#xD;
&#xD;
        -  To evaluate the effect of the administration of ferric carboxymaltose (Ferinject®) with&#xD;
           or without erythropoietin vs. no treatment (standard therapy) on pre- and postoperative&#xD;
           Hb levels, iron status, transfusion rate, days until discharge.&#xD;
&#xD;
        -  To evaluate the tolerability and safety of Ferinject®&#xD;
&#xD;
      Study Centres:&#xD;
&#xD;
      This is a single centre study&#xD;
&#xD;
      Patients:&#xD;
&#xD;
      A total of 75 completed patients (50 patients in the intravenous iron treatment groups and 25&#xD;
      patients in the no treatment group will be recruited.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      TREATMENT:&#xD;
&#xD;
      Patients will be randomised 1:1:1 to one of the following groups:&#xD;
&#xD;
      Group I - Ferinject ® and EPO treatment group 25 patients will be randomised to the Ferinject&#xD;
      and EPO treatment group.&#xD;
&#xD;
      For each patient, the cumulative total iron requirement will be calculated using the formula&#xD;
      of Ganzoni [Ganzoni et al, 1970]:&#xD;
&#xD;
      Iron deficit [mg] = b.w. [kg]† x (target Hb - actual Hb) [g/L] x 0.24†† + depot iron [mg]&#xD;
&#xD;
      † In patients with a body mass index (BMI = weight [kg] / (height [m] x height [m])) &gt;25, a&#xD;
      normalised weight will be used to calculate the iron deficit. Normalised weight [kg] = 25 x&#xD;
      height [m] x height [m].&#xD;
&#xD;
      †† Factor 0.24 = 0.0034 (iron content Hb = 0.34%) * 0.07 (blood volume = 7% of b.w.) * 1000&#xD;
      (conversion g to mg) Target Hb: 150 g/L Actual Hb: Value obtained at screening visit Depot&#xD;
      iron: 500 mg&#xD;
&#xD;
      Patients will receive a first dose of 1000 mg iron as Ferinject® 21 days prior to the&#xD;
      scheduled surgery. Patients will receive Ferinject® once weekly for up to two occasions (Day&#xD;
      -21 and Day -14) until the calculated cumulative dose is reached for that individual. The Day&#xD;
      -14 infusion may not be necessary, depending on the calculated total iron requirement for&#xD;
      each patient. Patients in treatment group 1 will get additionally a single 10000 IU dose of&#xD;
      EPO together on treatment day -14.&#xD;
&#xD;
      Group II - Ferinject ® treatment group 25 patients will be randomised to the Ferinject&#xD;
      without EPO.&#xD;
&#xD;
      For each patient, the cumulative total iron requirement will be calculated using the formula&#xD;
      of Ganzoni [Ganzoni et al, 1970]:&#xD;
&#xD;
      Iron deficit [mg] = b.w. [kg]† x (target Hb - actual Hb) [g/L] x 0.24†† + depot iron [mg]&#xD;
&#xD;
      † In patients with a body mass index (BMI = weight [kg] / (height [m] x height [m])) &gt;25, a&#xD;
      normalised weight will be used to calculate the iron deficit. Normalised weight [kg] = 25 x&#xD;
      height [m] x height [m].&#xD;
&#xD;
      †† Factor 0.24 = 0.0034 (iron content Hb = 0.34%) * 0.07 (blood volume = 7% of b.w.) *1000&#xD;
      (conversion g to mg) Target Hb: 150 g/L Actual Hb: Value obtained at screening visit Depot&#xD;
      iron: 500 mg&#xD;
&#xD;
      Patients will receive a first dose of 1000 mg iron as Ferinject 21 days prior to the&#xD;
      scheduled surgery. Patients will receive Ferinject® once weekly for up to two occasions (Day&#xD;
      -21 and Day -14) until the calculated cumulative dose is reached for that individual. The Day&#xD;
      -14 infusion may not be necessary, depending on the calculated total iron requirement for&#xD;
      each patient.&#xD;
&#xD;
      Group III - Control group 25 patients will receive the standard treatment for this patient&#xD;
      population (no anaemia treatment).&#xD;
&#xD;
      Primary Efficacy Endpoints&#xD;
&#xD;
      • Hb increase from baseline till day of surgery&#xD;
&#xD;
      Secondary Efficacy Endpoints&#xD;
&#xD;
        -  Percentage of patients reaching an Hb of &gt; 12 g/dl (women) or of &gt; 13 g/dl (men) at any&#xD;
           point in time during the study&#xD;
&#xD;
        -  Change in Hb level from baseline to highest Hb level during the study&#xD;
&#xD;
        -  Change in Ferritin value from baseline to highest ferritin value during the study&#xD;
&#xD;
        -  Change in Tsat value from baseline to highest Tsat value during the study&#xD;
&#xD;
        -  Transfusion rate&#xD;
&#xD;
        -  Infection rate&#xD;
&#xD;
        -  Days until discharge from hospital&#xD;
&#xD;
        -  Days until rehabilitation therapy&#xD;
&#xD;
      Secondary Safety Endpoints:&#xD;
&#xD;
        -  Adverse events: type, nature, incidence and outcome&#xD;
&#xD;
        -  Vital signs (temperature, blood pressure and heart rate)&#xD;
&#xD;
        -  Clinical laboratory panels (haematology/coagulation, clinical chemistry, except Hb and&#xD;
           iron status, which are considered to be efficacy endpoints)&#xD;
&#xD;
      Laboratory parameters:&#xD;
&#xD;
      Hematology/coagulation parameters to be analysed are Hb, haematocrit (Hct), red blood cell&#xD;
      count (RBC), white blood cell count (WBC) with differential and platelet count, mean&#xD;
      corpuscular volume (MCV), mean corpuscular haemoglobin (MCH), mean corpuscular haemoglobin&#xD;
      concentration (MCHC).&#xD;
&#xD;
      Clinical chemistry parameters to be analysed are alkaline phosphatase (AP), gamma-glutamyl&#xD;
      transpeptidase (GGT), aspartate aminotransferase (AST), alanine aminotransferase (ALT),&#xD;
      C-reactive protein (CRP), endogenous erythropoietin.&#xD;
&#xD;
      Iron status parameters include serum iron, serum ferritin, serum transferrin and TSAT.&#xD;
&#xD;
      Additional parameters - folic acid, vitamin B12 and beta-HCG will be analysed at baseline&#xD;
      only, creatinin, soluble transferrin receptor and total bilirubin will be analysed at all&#xD;
      visits.&#xD;
&#xD;
      Statistical Methods:&#xD;
&#xD;
      Summary statistics will be provided for safety and efficacy parameters as well as for the&#xD;
      patients' demographic characteristics. Data will be presented per visit, if appropriate. The&#xD;
      test for the primary endpoint is confirmative. Statistical tests of secondary endpoints will&#xD;
      be employed for exploratory purposes to highlight interesting comparisons (e.g., baseline&#xD;
      versus end of study) that may warrant further consideration. Unless otherwise specified, the&#xD;
      significance level of all statistical tests will be 5% with a two-sided alternative. If&#xD;
      appropriate, corresponding 95%-confidence intervals will be calculated. The sample size&#xD;
      estimation is based on t-test calculation.&#xD;
&#xD;
      Continuous variables will be summarized as mean +/- SD and median with range where&#xD;
      appropriate. Continuous variables will be compared using the Kruskal-Wallis test followed by&#xD;
      pairwise Mann-Whitney tests with Bonferroni-correction. Nominal variables will be compared&#xD;
      using the chi-square test or Fisher's exact test where appropriate. Changes within groups of&#xD;
      nominal variables will be analyzed using McNemar test.&#xD;
&#xD;
      Changes within groups of continuous variables will be analyzed using the Friedman test&#xD;
      followed by pairwise post hoc comparisons using the Wilcoxon signed rank test with Bonferroni&#xD;
      correction. Prevalence of anaemia will be presented with exact confidence interval (CI).&#xD;
      Continuous variables will be transformed to normal distribution, and CIs for the mean will be&#xD;
      computed. The limits of these CIs then will be retransformed to the original units and&#xD;
      interpreted as CIs for the median.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Not being able to recuit sufficient patients due to a lack of complience&#xD;
  </why_stopped>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hb increase from baseline till day of surgery</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>Iron Deficiency Anemia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo for EPO and for Ferinject ®</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Only Ferinject ® , Placebo for EPO</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ferinject ® + EPO</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ferinject ®</intervention_name>
    <description>iv administration in Arm 1 placebo NaCl 0.9% In arm 2 iv administration of Ferinject ® and subcutaneous NaCl 0.9 % as an EPO placebo In arm 3 iv administration of Ferinject ® and subcutaneous EPO</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  &gt; 18 years of age and signed written informed consent&#xD;
&#xD;
          -  Patients scheduled to undergo major orthopaedic surgery (hip or knee arthroplasty or&#xD;
             back surgery)&#xD;
&#xD;
          -  10 g/dl &lt; Hb &lt; 13.0 g/dl for men and 10 g/dl &lt; Hb &lt; 12.0 g/dl for women, at screening&#xD;
             ( 3 weeks prior to surgery)&#xD;
&#xD;
          -  Ferritin &lt; 100 μg/l or 100-300 with TSat &lt; 20%&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Suspicion of iron overload (Ferritin &gt;300 μg/l or/and TSAT&gt;50%)&#xD;
&#xD;
          -  Active severe infection/inflammation (defined as serum CRP &gt; 20 mg/l) or diagnosed&#xD;
             malignancy&#xD;
&#xD;
          -  Folate-and/or Vitamin B12 deficiency (according to local lab reference range)&#xD;
&#xD;
          -  Known history of hepatitis B/C or HIV-positive&#xD;
&#xD;
          -  Liver values 3 times higher than normal&#xD;
&#xD;
          -  Immunosuppressive or myelosuppressive therapy&#xD;
&#xD;
          -  A concurrent medical condition(s) that, in the view of the investigator, would prevent&#xD;
             compliance or participation or jeopardize the health of the patients.&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
&#xD;
          -  Transfusion within 1 month prior to study inclusion, EPO treatment with in the last 4&#xD;
             weeks, any iron treatment within 4 weeks prior to the inclusion in the trail&#xD;
&#xD;
          -  Participation in any other therapeutic trial within the previous month&#xD;
&#xD;
          -  History of thromboembolic events in the family or the patient&#xD;
&#xD;
          -  Severe peripheral, coronary or carotid artery disease&#xD;
&#xD;
          -  Bodyweight &lt; 50 kg&#xD;
&#xD;
          -  Patients not able to understand the German language&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Oliver Theusinger, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Zurich, Division of Anaesthesiology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Zurich, Division of Anaesthesiology</name>
      <address>
        <city>Zurich</city>
        <state>ZH</state>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <study_first_submitted>June 25, 2008</study_first_submitted>
  <study_first_submitted_qc>June 25, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2008</study_first_posted>
  <last_update_submitted>June 19, 2013</last_update_submitted>
  <last_update_submitted_qc>June 19, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 20, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Anemia, Iron-Deficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

